Cero Therapeutics Holdings, Inc 8-K, filed Feb 4, 2026
Cero Therapeutics Holdings, Inc. (CERO)
About this 8-K
Cero Therapeutics Holdings, Inc filed this 8-K on February 4, 2026.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
| (Address of principal executive offices) | (Zip Code) |
(
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | ||||
| None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Information.
CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), has prepared a poster presentation that will be presented at the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in the poster presentation is summary information that should be considered within the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The poster presentation speaks as of the date of this Current Report on Form 8-K. While the Company may elect to update the poster presentation in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Poster Presentation (February 2026) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: February 4, 2026 | CERO THERAPEUTICS HOLDINGS, INC. | |
| By: | /s/ Chris Ehrlich | |
| Name: | Chris Ehrlich | |
| Title: | Chief Executive Officer | |
2
Exhibit 99.1
CER - 1236 is a first - in - class chimeric antigen receptor T - cell (CAR - T) therapy designed to induce phagocytic target clearance through a TIM - 4 – based receptor ectodomain. TIM - 4 targets TIM - 4 - L, or phosphatidylserine, a structural phospholipid expressed on apoptotic and cancerous cells, especially acute myeloid leukemia, but absent on healthy cells. TIM - 4 binding to its ligand results in both cytotoxic T cell killing and phagocytosis of target cells. This non - canonical mechanism differs from cytotoxic CAR - T approaches and is intended to modulate target clearance with reduced systemic inflammatory toxicity. We report the first - in - human clinical experience with CER - 1236 in advanced myeloid malignancies. INTRODUCTION ϙϙϙϙϙϙϙϙ First - In - Human Clinical Experience with CER - 1236, a First - In - Class TIM - 4 – Based Phagocytic CAR - T Therapy, Including Platelet Transfusion Independence In an Index Patient with High - Risk MDS/AML (inv(3)/Mecom) 5(68/76 Preclinical safety results reveal no off - tumor cytotoxicity Figure 3. (A) CER - 1236 response to healthy primary human cells was assessed by co - culturing CER - 1236 T cells with primary human cells and response was measured at 24h by IFN - γ secretion. MV - 4 - 11 AML cells were used as a positive control. Mean ± SD is shown, n=3. **** = p <0.0001. (B) CER - 1236 cytotoxicity against select healthy primary human cells was assessed using LDH release at 72h post co - culture. MV - 4 - 11 AML cells were used as a positive control. Mean ± SD is shown, n=3. ** = p<0.01. 7,0 /LVSUHYDOHQWRQKXPDQ$0/EXWQRWKHDOWK\ERQHPDUURZ Figure 1. TIM - 4 - L expression was assessed on newly diagnosed AML or healthy donor BM aspirates by flow cytometry. (A) Percent TIM - 4 - L+ cells or (B) TIM - 4 - L gMFI was assessed in CD45dim live cells for AML, or CD45+ cells for healthy donors. Dotted lines divide graphs into tertiles. Mean ± SD is shown, N= 33 for AML, 8 for healthy donor. Black dots indicates samples with pretreatment. (C) Representative histograms of TIM - 4 - L expression on AML of each tertile or healthy donor BM. A. ϟ C. &(5 FRQVWUXFW Figure 2. CER - 1236 construct design. The CER - 1236 construct consists of a human TIM - 4 extracellular domain, which allows binding to TIM - 4 - L and confers intrinsic phagocytic activity. A CD28 transmembrane domain (TMD) as well as CD28 and CD3 ζ signaling domain, which allow for robust and rapid T cell activation and expansion, as well as the induction of cytotoxic cell killing. A TLR2 signaling domain promotes phagocytosis and modulates cytokine secretion. TMD &(5 0HFKDQLVPRI$FWLRQ CONCLUSIONS • CER - 1236, a first - in - class phagocytic CAR - T therapy targeting TIM - 4 ligand (TIM - 4L), was successfully manufactured and administered to all enrolled patients in a first - in - human trial, demonstrating the technical and clinical feasibility of this novel therapeutic approach. • In this first CAR - T experience targeting TIM - 4L, no adverse events suggestive of on - target toxicity were observed, supporting further clinical development of this approach. • No cytokine release syndrome (CRS) or immune effector cell – associated neurotoxicity syndrome (ICANS) of any grade was observed, despite incorporation of a CD28 costimulatory domain and measurable cell expansion, consistent with a non - cytotoxic, phagocytosis - driven mechanism of action. • In an index patient with inv(3) AML, multiple doses of CER - 1236 were administered without safety - limiting toxicity and were associated with durable platelet recovery and transfusion independence for 72 days, despite persistent cytogenetic abnormalities. Discordance between hematologic lineage recovery and cytogenetics suggests that CER - 1236 may modulate marrow function and support aspects of hematopoiesis without requiring full clonal eradication. • Collectively, these findings support clinical evaluation of CER - 1236 in additional myeloid disease contexts characterized by chronic inflammatory bone marrow microenvironments and elevated TIM - 4L expression, including myelodysplastic syndromes (MDS) and myelofibrosis (MF). TIM - 4 – mediated recognition and clearance of TIM - 4L ⁺ cells and cellular debris may help reprogram the inflammatory marrow niche and support normal hematopoiesis, as reflected by transfusion - based clinical endpoints. >ĖČŪŘôϙ ͖ ϟ ϙ ÍŜôīĖIJôϙèēÍŘÍèťôŘĖŜťĖèŜϙĺċϙôIJŘĺīīôîϙŕÍťĖôIJťŜϟϙīīϙēÍîϙēôÍŽĖīƅϙŕŘôťŘôÍťôîϙŘôīÍŕŜôîϯŘôċŘÍèťĺŘƅϙa[ϙ ϼ‡ϯ‡ϙa[Ͻϟϙ„ŘĖĺŘϙťēôŘÍŕĖôŜϙĖIJèīŪîôîϙFa ϱ æÍŜôîϙŘôČĖıôIJŜϠϙŽôIJôťĺèīÍƄϠϙĖIJťôIJŜĖŽôϙèēôıĺťēôŘÍŕƅϠϙ ĖIJŽôŜťĖČÍťĖĺIJÍīϙÍČôIJťŜϠϙÍIJîϙÍīīĺČôIJôĖèϙF‹ “ϟ bĺťôϡϙ„ÍťĖôIJťϙ ͏͏͓ ϱ ͏͏͐ϙ ēÍîϙēĖČē ϱ ŘĖŜħϙèƅťĺČôIJôťĖèŜϙſĖťēϙĖIJŽϼ ͒ Ͻϼŗ ͑͐ ŗ ͕͑ ϽϙĖIJŽĺīŽĖIJČϙa( iaϙϼ(«I ͐ ϽϙĺIJϙæĺťēϙ èēŘĺıĺŜĺıôϙ ͒ϙ ēĺıĺīĺČŪôŜϙϼ ͐͏͏ ҇ϙıôťÍŕēÍŜôŜϙæƅϙħÍŘƅĺťƅŕôϢϙѹ ͕͔ ҇ϙĖIJťôŘŕēÍŜôϙèôīīŜϙæƅϙ>I‹FϽϙÍIJîϙÍϙ èĺIJèŪŘŘôIJťϙîôīϼ ͑͏ ŗϽϙŕŘôŜôIJťϙĖIJϙѹ ͓͘ ҇ϙĺċϙĖIJťôŘŕēÍŜôϙèôīīŜϟϙI‹ bϡϙ ͓͕ Ϡ³´ϠĖIJŽϼ ͒ Ͻϼŗ ͑͐ ŗ ͕͑ ϽƄ ͑ Ϡîôīϼ ͑͏ Ͻϼŗ ͐͐ϟ͑ ŗ ͐͒ϟ͐ Ͻϟϙ (IJťôŘĖIJČϙťēĖŜϙťŘĖÍīϠϙťēôϙŕÍťĖôIJťϙſÍŜϙťŘÍIJŜċŪŜĖĺIJϙîôŕôIJîôîϙċĺŘϙæĺťēϙŕīÍťôīôťŜϙÍIJîϙŘôîϙæīĺĺîϙèôīīŜϟ Figure 8. Summary of Grade ≥3 treatment - emergent adverse events (TEAEs) by patient, cohort, and study day in the safety analysis set. Adverse events were graded per CTCAE v5.0, with relatedness assessed by the investigator. No cytokine release syndrome (CRS) or immune effector cell – associated neurotoxicity syndrome (ICANS) of any grade was observed. No dose - limiting toxicities (DLTs) or treatment - related severe adverse events were observed during the 28 - day DLT assessment window. Serious adverse events were febrile neutropenia, tumor lysis syndrome, generalized weakness, and myocardial infarction, and were not deemed treatment - related. One Grade 5 myocardial infarction occurred after disease progression and initiation of off - protocol chemotherapy and was not considered treatment - related (see below). >ĖČŪŘôϙ ͘ ϟϙ ‹ſĖı ϱ īÍIJôϙťĖıôīĖIJôŜϙîôŕĖèťϙĖIJîĖŽĖîŪÍīϙŕÍťĖôIJťϙèĺŪŘŜôŜϙċŘĺıϙƱŘŜťϙîĺŜôϙϼaĺIJťēϙ ͏ ϽϙťĺϙôIJîϙĺċϙŜťŪîƅϙ ϼ(i‹ϽϟϙīŪôϙÍŘŘĺſŜϙĖIJîĖèÍťôϙîĺŜĖIJČϙôŽôIJťŜϙϼ["ϙѱϙīƅıŕēĺîôŕīôťĖĺIJϢϙ (‡ ϱ ͕͐͑͒ϙ ѱϙ ‡ ϱ “ϙèôīīϙĖIJċŪŜĖĺIJϽϢϙēĺŘĖƏĺIJťÍīϙ æÍŘŜϙĖIJîĖèÍťôϙĺIJ ϱ ŜťŪîƅϙîŪŘÍťĖĺIJϟϙ„ôŘϙŕŘĺťĺèĺīϠϙÍîîĖťĖĺIJÍīϙ (‡ ϱ ͕͐͑͒ϙ ĖIJċŪŜĖĺIJŜϙſôŘôϙŕôŘıĖťťôîϙÍťϙĖIJŽôŜťĖČÍťĺŘϙ îĖŜèŘôťĖĺIJϠϙſĖťēϙĺŘϙſĖťēĺŪťϙīƅıŕēĺîôŕīôťĖĺIJϟϙ„ôŘèôIJťÍČôŜϙŜēĺſIJϙĖIJϙôÍèēϙťĖıôīĖIJôϙŘôŕŘôŜôIJťϙıÍŘŘĺſϙæīÍŜťϙ ŕôŘèôIJťÍČôϙæƅϙæĺIJôϙıÍŘŘĺſϙæĖĺŕŜƅϟϙbĺϙĺæĤôèťĖŽôϙıÍŘŘĺſϙĺŘϙŕôŘĖŕēôŘÍīϙæīĺĺîϙŘôŜŕĺIJŜôŜϙſôŘôϙĺæŜôŘŽôîϟϙ (i‹ϙŘôÍŜĺIJŜϡϙ ͏͏͐ ϱ ͏͏͐ ϠϙŕÍťĖôIJťϙŘôŗŪôŜťϢϙ ͏͏͓ ϱ ͏͏͐ϙ ϼĖIJîôƄϽϠϙîĖŜôÍŜôϙŕŘĺČŘôŜŜĖĺIJϙÍIJîϙèīĖIJĖèÍīϙîôèīĖIJôϢϙ ͏͏͔ ϱ ͏͏͑ Ϡϙ ŕŘĺČŘôŜŜĖŽôϙîĖŜôÍŜôϢϙ ͏͏͔ ϱ ͏͏͒ ϠϙŜôŘĖĺŪŜϯĖIJťĺīôŘÍæīôϙÍîŽôŘŜôϙôŽôIJťϟ „ÍťĖôIJťϙ ͏͏͔ ϱ ͏͏͒ ϡϙ>ĺīīĺſĖIJČϙÍϙ"Íƅϙ ͑͗ϙ aϙæīÍŜťϙŕôŘèôIJťÍČôϙĺċϙ ͓͏ ҇ϙÍċťôŘϙťēôϙƱŘŜťϙĖIJċŪŜĖĺIJϠϙÍîîĖťĖĺIJÍīϙ (‡ ϱ ͕͐͑͒ϙ îĺŜĖIJČϙſÍŜϙÍîıĖIJĖŜťôŘôîϙŕôŘϙĖIJŽôŜťĖČÍťĺŘϙîĖŜèŘôťĖĺIJϙċĺŘϙŘôīÍŕŜôîϯŘôċŘÍèťĺŘƅϙa[ϟϙ“ſĺϙ (‡ ϱ ͕͐͑͒ϙ ĖIJċŪŜĖĺIJŜϙ ſĖťēĺŪťϙīƅıŕēĺîôŕīôťĖĺIJϙſôŘôϙČĖŽôIJϙÍťϙaĺIJťēϙ ͐ϙ ϼ ͑ ѯ ͐͏ ϊϙ èôīīŜϯħČϠϙťēôIJϙ ͐ ѯ ͐͏ ϊϙ èôīīŜϯħČϙťſĺϙîÍƅŜϙīÍťôŘϽϟϙ“ſĺϙſôôħŜϙ īÍťôŘϠϙťēôϙŕÍťĖôIJťϙſÍŜϙēĺŜŕĖťÍīĖƏôîϙſĖťēϙŕŘĺČŘôŜŜĖŽôϙīôŪħôıĖÍϙϼ® ϙ ͒͐ϟ͘ ѯ ͐͏ ύ ϯ[ϽϠϙťŘÍIJŜĖťĖĺIJôîϙĺƯϙŕŘĺťĺèĺīϙťĺϙ ƲŪîÍŘÍæĖIJôϯèƅťÍŘÍæĖIJôϙŜÍīŽÍČôϙťēôŘÍŕƅϠϙôƄŕôŘĖôIJèôîϙÍIJϙÍèŪťôϙıƅĺèÍŘîĖÍīϙĖIJċÍŘèťĖĺIJϙŜĖƄϙîÍƅŜϙīÍťôŘϠϙÍIJîϙîĖôîϙťēôϙ ċĺīīĺſĖIJČϙîÍƅϙÍċťôŘϙťŘÍIJŜĖťĖĺIJϙťĺϙèĺıċĺŘťϙèÍŘôϠϙŕŘĖĺŘϙťĺϙ(i‹ϟ Figure 10. Serial platelet counts with platelet transfusion events (red circles), bone marrow (BM) blast percentages, cytogenetic assessment of the inv(3)(q21q26.2) – associated clone, and timing of CER - 1236 administrations (blue arrows) with or without lymphodepleting (LD) chemotherapy. The index patient achieved platelet independence for 72 consecutive days (D71 – D143). BM blasts were assessed by morphology and/or flow cytometry from paired aspirate and core biopsy specimens. Cytogenetic analyses demonstrated persistent inv(3)(q21q26.2) – associated disease despite platelet lineage recovery following the initial three CER - 1236 infusions. Given persistent cytogenetic disease, LD + CER - 1236 was re - initiated per protocol to attempt deeper disease control. Following the second LD + CER - 1236 administration, the patient experienced a rapid change in disease trajectory, with rising BM blast percentages and progressive functional impairment, leading to end of study due to substantial disease progression and clinical decline. Successful Manufacture and Release of CER - 1236 For All Patients Enrolled Pt 005 - 003 Pt 005 - 002 Pt 004 - 001 Pt 001 - 001 2212.5 2147.5 2032.5 622.5 Total cell yield (x10^6) 95.6 92.2 88.6 82.6 Viability (%) 99.2 94.9 95.6 99.6 CD3+% 34.3 60.9 51.3 51.4 CER+% 7 6 6 1 Final product (bag) Figure 5. CER - 1236 T cells manufactured on a Miltenyi Prodigy platform using a 7 - day manufacturing process. CER - 1236 Demonstrates Robust Expansion and Persistence that is Not Associated with Inflammatory Cytokine Secretion >ĖČŪŘôϙ ͕ ϟϙϼϽϙ„ēÍŘıÍèĺħĖIJôťĖèŜϙĺċϙ (‡ ϱ ͕͐͑͒ϙ ſÍŜϙÍŜŜôŜŜôîϙæƅϙîî„ ‡ϙĖIJϙŕôŘĖŕēôŘÍīϙæīĺĺîϟϙ ıÍƄϙ ĺèèŪŘŘôîϙæôťſôôIJϙ ͐͏ϙ ÍIJîϙ ͓͐ îÍƅŜϙŕĺŜťϙĖIJċŪŜĖĺIJϟϙϼϽϙI>b ϱ ̌Ϡϼ ϽϙI[ ϱ ͑ Ϡϙϼ"Ͻϙ“b> ϱ ̊ ϠϙÍIJîϙϼ(ϽϙI[ ϱ ͕ϙ ſôŘôϙ ıôÍŜŪŘôîϙĖIJϙŕôŘĖŕēôŘÍīϙæīĺĺîϙŪŜĖIJČϙi ϱ īĖIJħϙ“ÍŘČôťϙ ͓͗ϙ èƅťĺħĖIJôϙŕÍIJôīϟϙ Figure 4. Phase 1/1b study using a standard 3+3 dose - escalation design followed by dose expansion to evaluate the safety, tolerability, and preliminary activity of CER - 1236 in AML. At dose levels incorporating two administrations ( × 2), CER - 1236 was administered as split dosing on Day 0 and Day 2. This poster summarizes the clinical experience of the first four treated patients. 3KDVH VWXG\GHVLJQHYDOXDWLQJ&(5 LQ KHPDWRORJLFPDOLJQDQFLHV 1&7 Figure 11. Based on these results, the study was expanded to include transfusion - dependent MDS (TD - MDS), high - risk MDS (HR - MDS), and myelofibrosis (MF) after JAK inhibitor failure, reflecting the hypothesis that TIM - 4 – based phagocytic CAR - T therapy may modulate the inflammatory bone marrow microenvironment and support hematopoietic recovery beyond cytoreduction. Expansion of CER - 1236 Clinical Study Into Myelodysplastic Disease and Myelofibrosis /XNH0RXQWMR\'2 5REHUW6LNRUVNL0'3K' %UDQGRQ&LHQLHZLF]3K' .ULVWHQ3LHUFH3K' +RQJ[LX1LQJ3K' (OL]DEHWK 3DGLOOD%6 1HLO6DQNDU0' 0LFKDHO%0DULV0' 6WHSKHQ$6WULFNODQG0' DQG$EKLVKHN0DLWL0' &RORUDGR%ORRG&DQFHU,QVWLWXWH6DUDK&DQQRQ5HVHDUFK,QVWLWXWH'HQYHU&2 &(5R 7KHUDSHXWLFV+ROGLQJV,QF6RXWK 6DQ)UDQFLVFR&$ 6DUDK&DQQRQ5HVHDUFK,QVWLWXWHDW7UL6WDU&HQWHQQLDO1DVKYLOOH71 7KH8QLYHUVLW\RI7H[DV0' $QGHUVRQ&DQFHU &HQWHU +RXVWRQ7; A. B. ϟ D. (ϟ Baseline Demographics, Disease Characteristics, and Prior Therapy Grade ≥3 Treatment - Emergent Adverse Events /RQJLWXGLQDOKHPDWRORJLFDQGF\WRJHQHWLFFRXUVH GHPRQVWUDWLQJGXUDEOHSODWHOHWUHFRYHU\ZLWK F\WRJHQHWLFSHUVLVWHQFHLQDQLQGH[SDWLHQW Patient - Level Study Timelines (First Dose to End of Study)